Blog

UICC Highlights AI and Biomarker Advances in Lung Cancer Detection and Treatment

Sam Hare/LinkedIn

May 29, 2025, 12:43

UICC Highlights AI and Biomarker Advances in Lung Cancer Detection and Treatment

Union for International Cancer Control (UICC) shared a post on LinkedIn:

“AI has a huge potential to revolutionise how we treat cancer.” – Sam Hare, CEO & Co-Founder The HLH Imaging Group.

Advancements in technology, like AI-assisted imaging and biomarker testing, are transforming the early detection of lung cancer. By identifying cancer at more treatable stages, these innovations improve survival rates and lead to more precise treatments.

AI’s ability to analyse vast data sets helps detect tumours early, while biomarker testing enables targeted therapies, reducing trial-and-error approaches. To maximise these benefits, it’s crucial to support research and integrate these technologies into healthcare systems globally.

With continued investment, AI can significantly improve cancer care, offering hope for better outcomes and saving lives.”

UICC emphasized the transformative role of AI-assisted imaging and biomarker testing in improving early lung cancer detection and treatment precision, advocating for continued global research and integration into healthcare systems.

More posts featuring Union for International Cancer Control.

AI cancer cancer care fight against cancer Global fight against cancer Lung cancer OncoDaily Oncology Sam Hare The HLH Imaging Group UICC Union for International Cancer Control

USA vs Europe: Who Does Cancer Screening Better?

A Call for Peace from the Frontlines of Pediatric Oncology by the POEM Group

Servier Acquires Precision Therapy for Acute Leukemias from BioNova Pharmaceuticals

Penn Medicine: Cancer Center Near Me

Elevating Childhood Cancer and Catastrophic Diseases in the Global NCD Agenda: Joint Call to Action